Inotropic, vasodilating and preconditioning actions of levosimendan in the heart

Thoracic and Cardiovascular Surgeon

Volumn 56, Issue 7, 2008, Pages 379-385

  Meyer, K ^a   Schipke, Joshen D ^a   Klocke, R C ^b   Gams, E ^a   Korbmacher, B ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Marienhospital ^*  (Germany)

Author keywords

Cardiovascular surgery; Coronary bypass surgery; Myocardial protection

Indexed keywords

LEVOSIMENDAN; PLACEBO;

ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY VASCULAR RESISTANCE; DIASTOLE; HEART ARRHYTHMIA; HEART HEMODYNAMICS; HEART INFARCTION PREVENTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PERFUSION; HEART PROTECTION; HEART RATE; HEART STROKE VOLUME; HEART SURGERY; INOTROPISM; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY; STATISTICAL SIGNIFICANCE; VASODILATATION;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CALCIUM; CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART; HEMODYNAMICS; HYDRAZONES; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; OXYGEN CONSUMPTION; POTASSIUM CHANNELS; PYRIDAZINES; RABBITS; VASODILATOR AGENTS;

EID: 55049138629     PISSN: 01716425     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1038729     Document Type: Article

References (47)

1. Rooke GA, Feigl EO. Work as a correlate of canine left ventricular oxygen consumption, and the problem of catecholamine oxygen wasting. Circ Res 1982; 50: 273-286
2. Rehberg S, Ertmer C, Van AH, Lange M, Broking K, Morelli A, Westphal M. [Role of levosimendan in intensive care treatment of myocardial insufficiency]. Anaesthesist 2007; 56: 30-43
3. 2+.Ann Med 2002; 34: 248-258
4. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther 1997; 283: 375-383
5. Light PE. Cardiac KATP channels and ischemic preconditioning: current perspectives. Can J Cardiol 1999; 15: 1123-1130
6. Das B, Sarkar C. Cardiomyocyte mitochondrial KATP channels participate in the antiarrhythmic and antiinfarct effects of KATP activators during ischemia and reperfusion in an intact anesthetized rabbit model. Pol J Pharmacol 2003; 55: 771-786
7. Schulz R, Rose J, Heusch G. Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine. Am J Physiol 1994; 267: H1341-H1352
8. Busk M, Maeng M, Kristensen J, Berg JS, Mortensen UM, Nielsen TT, Nielsen-Kudsk JE. Effects of levosimendan on myocardial infarct size and hemodynamics in a closed-chest porcine ischemia-reperfusion model. Cardiovasc Drugs Ther 2006; 20: 335-342
9. Lepran I, Pollesello P, Vajda S, Varro A, Papp JG. Preconditioning effects of levosimendan in a rabbit cardiac ischemia-reperfusion model. J Cardiovasc Pharmacol 2006; 48: 148-152
10. Headrick JP. Aging impairs functional, metabolic and ionic recovery from ischemia-reperfusion and hypoxia-reoxygenation. J Mol Cell Cardiol 1998; 30: 1415-1430
11. Rüegg JC. The vertebrate heart: modulation of calcium control. In: Rüegg JC (ed). Calcium in Muscle Contraction. Berlin, Heidelberg, New York: Springer, 1992: 165-200
12. Rump AF, Acar D, Klaus W. A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts. Br J Pharmacol 1994; 112: 757-762
13. du Toit EF, Muller CA, McCarthy J, Opie LH. Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 1999; 290: 505-514
14. Todaka K, Wang J, Yi GH, Stennett R, Knecht M, Packer M, Burkhoff D. Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther 1996; 279: 120-127
15. 2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol 1998; 30: 1115-1128
16. (2+) sensitizer levosimendan in human myocardium. Am J Physiol Heart Circ Physiol 2002; 282: H131-H137
17. 2+ sensitizers caffeine and CGP 48506 on the relaxation rate of rat skinned cardiac trabeculae. Circ Res 1997; 80: 682-687
18. ++ sensitizers impair cardiac relaxation in failing human myocardium. J Pharmacol Exp Ther 1997; 280: 247-254
19. ++ sensitization in stunned myocardium. J Mol Cell Cardiol 1997; 29: 2053-2066
20. Hgashiyama A, Watkins MW, Chen Z, LeWinter MM. Effects of EMD 57033 on contraction and relaxation in isolated rabbit hearts. Circulation 1995; 92: 3094-3104
21. Tamargo J, Lopez-Sendon J. [Rationale and clinical evidence for the effects of new pharmacological treatments for heart failure]. Rev Esp Cardiol 2004; 57: 447-464
22. Barraud D, Faivre V, Damy T, Welschbillig S, Gayat E, Heymes C, Payen D, Shah AM, Mebazaa A. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone. Crit Care Med 2007; 35: 1376-1382
23. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004; 43: 2177-2182
24. Lehtonen LA, Antila S, Pentikainen PJ. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet 2004; 43: 187-203
25. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, Foster E, Chatterjee K. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005; 111: 1504-1509
26. Kaheinen P, Pollesello P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 2001; 37: 367-374
27. Erdei N, Papp Z, Pollesello P, Edes I, Bagi Z. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. Br J Pharmacol 2006; 148: 696-702
28. 2)-utilization in stunned myocardium: influence of ischemic preconditioning. Eur J Cardiothorac Surg 2001; 20: 770-776
29. Trines SA, Slager CJ, Onderwater TA, Lamers JM, Verdouw PD, Krams R. Oxygen wastage of stunned myocardium in vivo is due to an increased oxygen cost of contractility and a decreased myofibrillar efficiency. Cardiovasc Res 2001; 51: 122-130
30. Cohen MV, Baines CP, Downey JM. Ischemic preconditioning: from adenosine receptor of KATP channel. Annu Rev Physiol 2000; 62: 79-109
31. Post H, Heusch G. Ischemic preconditioning. Experimental facts and clinical perspective. Minerva Cardioangiol 2002; 50: 569-605
32. Kopustinskiene DM, Pollesello P, Saris NE. Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol 2001; 428: 311-314
33. Gross GJ, Fryer RM. Sarcolemmal versus mitochondrial ATP-sensitive K+ channels and myocardial preconditioning. Circ Res 1999; 84 (9): 973-979
34. Tritapepe L, De Santis V, Vitale D, Santulli M, Morelli A, Nofroni I, Puddu PE, Singer M, Pietropaoli P. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. Br J Anaesth 2006; 96: 694-700
35. Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000; 90: 5-11
36. Maytin M, Leopold J, Loscalzo J. Oxidant stress in the vasculature. Curr Atheroscler Rep 1999; 1: 156-164
37. Gasser R, Gasser S, Hammerl R, Hecking C. ATP-abhängige Kaliumkanäle im Herz-Kreislauf-System. J Kardiol 2003; 10 (Suppl C): 3-5
38. 2+ transients under acidotic condition in aequorin-loaded canine ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 440-448
39. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998; 98: 2141-2147
40. Vegh A, Szekeres L, Parratt JR. Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anaesthetized dogs. Br J Pharmacol 1991; 104: 294-295
41. Sun W, Wainwright CL. The potential antiarrhythmic effects of exogenous and endogenous bradykinin in the ischaemic rat heart in vivo. Coron Artery Dis 1994; 5: 541-550
42. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-1136
43. Marktanner R, Nacke P, Feindt P, Hohlfeld T, Schipke JD, Gams E. Delayed preconditioning via angiotensin-converting enzyme inhibition: pros and cons from an experimental study. Clin Exp Pharmacol Physiol 2006; 33: 787-792
44. Tosaki A, Hearse DJ. Protective effect of transient calcium reduction against reperfusion-induced arrhythmias. Am J Physiol 1987; 253: H225-H233
45. Leesar MA, Stoddard MF, Dawn B, Jasti VG, Masden R, Bolli R. Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation 2001; 103: 2935-2941
46. Wang X, Wei M, Kuukasjarvi P, Laurikka J, Jarvinen O, Rinne T, Honkonen EL, Tarkka M. Novel pharmacological preconditioning with diazoxide attenuates myocardial stunning in coronary artery bypass grafting. Eur J Cardiothorac Surg 2003; 24: 967-973
47. Kumar S, Kumar A, De Santis V. The preconditioning effects of levosimendan. Br J Anaesth 2006; 97: 425